Complement Therapeutics, Ltd.

Scion Life Sciences, an affiliate of the health care investment firm Petrichor, launched on 7 February with two friends and former Apple Tree Partners (ATP) colleagues – Scion co-founders and managing

The second quarter of 2023 was a good news bad news situation for venture capital investment in biopharmaceutical companies, according to the latest Venture Monitor report from Pitchbook and the Natio

The impressive €1.35bn ($1.5bn) sum that Forbion raised recently for its two newest funds demonstrates institutional investor belief in the sector, the European venture capital firm said, even while m

Armed with an eyebrow-raising sum from its series A financing, Complement Therapeutics, Ltd. is ramping up its developments for a gene therapy that the Germany-based biotech believes can transform t